A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection

A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection

Show other versions (1)

<h4>Background</h4> Coronavirus disease 2019 (COVID-19) is an immunoinflammatory and hypercoagulable state that contributes to respiratory distress, multi-organ dysfunction, and mortality. Dipyridamole, by increasing extracellular adenosine, has been postulated to be protective for COVID...

Full description

Bibliographic Details
Main Authors: Amit Singla, Nicholas B. Dadario, Ashima Singla, Patricia Greenberg, Rachel Yan, Anil Nanda, Detlev Boison, Rakesh Malhotra, Sunil Patel, Suri Nipun, Kaur Maninderpal, Dorothy Castro, Sanaa Bdiiwi, Hala Boktor, Htay Htay Kyi, Anne Sutherland, Amee Patrawalla, Kevin Ly, Yingda Xie, Ashish Sonig, Priyank Khandelwal, James Liu, Joseph Koziol, Diana Finkle, Sara Subanna, Steven K. Libutti
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886260/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886260/?tool=EBI

Similar Items